Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Matml74
No they would not need to do another trial. The trials do not measure reduction vs placebo in every possible symptom outcome due to covid. The primary endpoints are quite simple. Time to recovery vs placebo, deaths vs placebo etc etc.
The whole thing is very speculative and the current trial does not in any way address it. It has no bearing on the current activity or shareprice of the company.
Thanks for all the replies. So I’m assuming there could be benefit. Would that mean another trial would need to be conducted to measure reduced heart inflammation with SNG patients.
I guess I’m trying to ask is if P3 sprinter goes well would another trial have to happen to specifically measure this ?
Sorry if it’s a dumb question
Number of articles out there on the web
“Type I interferon is a therapeutic target for virus-induced lethal vascular damage“
IFN has been trialed by another company as treatment for organ failure ( intravenous IFN Beta1a ) .
https://clinicaltrials.gov/ct2/show/NCT03119701
It was stopped as they had complications caused by steroids ( as with the I/V trial on ARDS )
Both trials were run at a similar time , when they didn't know what was causing the issue ( steroids mainly , but the organ trial left much to be learnt )
https://www.researchsquare.com/article/rs-732466/v2
But given what they now know , IFN should in theory help with vascular issues and organ protection , it just needs to be given in the right situation and taking account of what other drugs are being used at the same time .
My take is that SNG001 is the better allround tool for COVID ,helping put IFN into the lungs given early via nebulizer , but given intravenously it may also be very effective ( without steroids ) , for patients whose lungs may have lost the proper function . I/V delivery may also help with vascular issues ( a big side symptom of Covid ) - due to the much higher dose entering the bloodstream . But it's the lack of lung function that may cause the organ failure in the first place , so if you can keep the lungs functioning , you hopefully help prevent it anyway .
That's my take on it , although I'm no expert .
Hopefully in time , both methods will be proven to be sound treatments .
The only mechanism I can see is that since SNG001 reduces viral load in the lung, then there are less infectious particles free or expelled to invade other tissues or organs and overall infectious severity is reduced. There could be a critical mass of viral disease that is needed to cause other vascular damage.
As the lungs absorb oxygen and transfer it to the vascular system I would imagine that it will do the same with other things that are inhaled. I'm not saying, because I don't know, that sng001 will help treat vascular disease. It does sound plausible in this respect though?
Do not forget the nebulisers which can be used at a patients home
Do not forget pulmonary
Common sense would suggest that vascular treatments would require injection into the blood. SNG001 targets the lungs and only a tiny amount makes it to the blood. Just my layman's view.
Hello
I’m intrigued to know if there has been any discussions or thoughts if SNG001 can help reduce inflammation of the heart or be shown to reduce myocardial disease in patients? I have always seen it as a treatment for patients with Pneumonia from covid . Keen to know if there is any hypothetical reason it could also reduce vascular issues.